Clinical trials: Minimal Disease, Residual
Cutaneous Squamous Cell Carcinoma
ctDNA in Cutaneous Squamous Cell Carcinoma
The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response…
- Trial name
- NCT06875609
- Testing
- Blood and Tissue Collection
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Massachusetts Eye and Ear Infirmary
Lymphoma
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas
To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the…
- Trial name
- NCT05676450
- Testing
- cell-free DNA
- Where
- 2 sites in United States
- Volunteers
- 517 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission
Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies
This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, JAK2 Gene Mutation
- Trial name
- NCT03272633
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Irradiated Allogeneic Cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rutgers, The State University of New Jersey
Multiple Myeloma, Minimal Residual Disease
A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment
The aim of this study was to observe the rate of MRD conversion and the impact on survival in newly diagnosed multiple myeloma (NDMM) patients with persistent MRD positivity after induction and consolidation therapy (autologous…
- Trial name
- MRD (NCT06109233)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- FengYan Jin
Acute Myeloid Leukemia
MRD Response-adapted Allo-HSCT for Adverse-risk AML
This TROPHY-AML01 regimen aims to identify the effectiveness and safety of MRD response-adapted allo-HSCT for adverse-risk acute myeloid leukemia in an open-label, randomized, controlled trial.
- Trial name
- NCT06301425
- Testing
- Intervention group, Control group
- Where
- China
- Volunteers
- 178 people
- Sponsor
- Peking University People's Hospital
CLL, SLL
A Time-Limited Approach to Treatment With Ibrutinib for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
The purpose of this study is to find out whether people with CLL or SLL who are currently receiving treatment with ibrutinib can stop treatment and remain off-treatment for at least 12 months, if they have achieved complete or…
- Conditions
- CLL, SLL, CLL/SLL, Chronic Lymphocytic Leukemia
- Trial name
- NCT04694560
- Testing
- Treatment Free Observation
- Where
- 2 sites in United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
High-risk Diffuse Large B-cell Lymphoma
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
The study will estimate the MRD-negative response rate after treatment with blinatumomab in subjects with high-risk DLBCL who are MRD-positive following aHSCT.
- Trial name
- NCT03298412
- Testing
- Blinatumomab
- Where
- 32 sites in United States, Australia and 5 more
- Volunteers
- 10 people
- Sponsor
- Amgen
Colorectal Cancer, Minimal Residual Disease
Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)
To find the highest and/or recommended dose of TROP2-CAR-NK cells combined with cetuximab in participants with MRD CRC.
- Trial name
- NCT06358430
- Testing
- Fludarabine Phosphate, Cyclophosphamide, Cetuximab
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
Natural Killer Cells Infusion for Treating Acute Myeloid Leukemia Patients With Minimal Residual Disease
This trial will evaluate the effectiveness and safety of haploid donor-derived in vitro activated natural killer(NK) cells infusion for Treating acute myeloid leukemia Patients With minimal residual disease.
- Trial name
- NCT04209712
- Testing
- haploid allogeneic NK cell therapy
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China
HPV, Oropharynx Cancer
A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC)
This study will look at whether monitoring HPV ctDNA levels is an effective way to detect cancer relapse risk in people with HPV-OPC.
- Conditions
- HPV, Oropharynx Cancer, HPV-Related Carcinoma, HPV-Related Malignancy
- Trial name
- NCT05307939
- Testing
- HPV ctDNA Assay, MRI Studies, EORTC QLQ H&N 35 and C30
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Lymphoblastic Leukemia
BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
This investigator-initiated, prospective, single-arm, multicenter clinical trial aims to evaluate the efficacy and safety of BEBT-908 (a HDAC/PI3Kα inhibitor provided by BeBetter Med Inc ,Guangzhou, China) combined with…
- Trial name
- NCT07301138
- Testing
- BEBT-908, Cyclophosphamide, Vincristine
- Where
- China
- Volunteers
- 23 people
- Sponsor
- Ruijin Hospital
Colorectal Neoplasms, Colorectal Cancer (Diagnosis)
MRD Monitoring in Colorectal Cancer Using ctDNA
This clinical study evaluates the use of free circulating tumor DNA (ctDNA) analysis from peripheral blood, known as liquid biopsy.
- Conditions
- Colorectal Neoplasms, Colorectal Cancer (Diagnosis), Minimal Residual Disease
- Trial name
- RezidRAS (NCT07895459)
- Testing
- Blood draw for ctDNA analysis
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- Masaryk Memorial Cancer Institute
Multiple Myeloma, Amyloidosis
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple…
- Trial name
- NCT04991103
- Testing
- DaraVRD/DaraVCD
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Alabama at Birmingham
Triple Negative Breast Cancer
A Trial Using ctDNA Blood Tests to Detect Cancer Cells After Standard Treatment to Trigger Additional Treatment in Early Stage Triple Negative Breast Cancer Patients
c-TRAK TN is a multi-centre phase II study, consisting of a circulating tumour DNA (ctDNA) surveillance component and a therapeutic component.
- Trial name
- c-TRAK-TN (NCT03145961)
- Testing
- Pembrolizumab
- Where
- 17 sites in United Kingdom
- Volunteers
- 208 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Leukemia, Myeloid, Acute
Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment
ERASE is part of the MyeloMATCH initiative, Young Adult Basket and is a Tier 2 study. The study is comparing the use of Cytarabine to Cytarabine and Venetoclax, Daunorubicin/Cytarabine Liposome and Venetoclax, and Azacitidine and…
- Trial name
- ERASE (NCT05628623)
- Testing
- Cytarabine, Venetoclax, CPX-351
- Volunteers
- 184 people
- Sponsor
- Eastern Cooperative Oncology Group
Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia
Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease
This phase II trial studies how well inotuzumab ozogamicin works in treating patients with B-cell acute lymphocytic leukemia with positive minimal residual disease.
- Conditions
- Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia
- Trial name
- NCT03441061
- Testing
- Inotuzumab Ozogamicin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma Resectable, Surgery
Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma
The aim of this study was to compare the accuracy of ctDNA-MRD longitudinal surveillance model and internationally accepted pathological MVI results in predicting recurrence after radical hepatectomy.
- Conditions
- Hepatocellular Carcinoma Resectable, Surgery, Recurrence
- Trial name
- NCT06449846
- Testing
- circulating tumor cell DNA detection
- Where
- 4 sites in China
- Volunteers
- 152 people
- Sponsor
- Zhujiang Hospital
Minimal Residual Disease, Fertility Preservation
Contamination of Testicle Tissue by RT-PCR in Participants With Solid Tumors
For prepubertal patients, cryopreservation of testicular tissue is the only option available to preserve their fertility before cancer treatment.
- Trial name
- TESTIMAR (NCT02400970)
- Testing
- malignant cells
- Where
- France
- Volunteers
- 40 people
- Sponsor
- University Hospital, Clermont-Ferrand
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia
This phase II trial studies how well azacitidine and venetoclax with or without pembrolizumab work in treating older patients with newly diagnosed acute myeloid leukemia.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, Secondary Acute Myeloid Leukemia
- Trial name
- NCT04284787
- Testing
- Azacitidine, Biopsy Procedure, Biospecimen Collection
- Where
- 29 sites in United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Hematologic Malignancy, Leukemia
Better Leukemia Diagnostics Through AI (BELUGA)
To the best of our knowledge, BELUGA will be the first prospective trial investigating the usefulness of deep learning-based hematologic diagnostic algorithms.
- Conditions
- Hematologic Malignancy, Leukemia, Minimal Residual Disease, Lymphoma
- Trial name
- BELUGA (NCT04466059)
- Testing
- Automated AI-Guided Diagnosis of Hematological Malignancies
- Where
- Germany
- Volunteers
- 25,000 people, healthy volunteers welcome
- Sponsor
- Munich Leukemia Laboratory